ANORO ELLIPTA INHALATION POWDER 62.5 MCG/25 MCG [SIN14838P]
Active ingredients: (UMEC STRIP) UMECLIDINIUM BROMIDE (MICRONISED) 74.2 MCG/DOSE EQV UMECLIDINIUM | (VI STRIP) VILANTEROL TRIFENATATE (MICRONISED) 40 MCG/DOSE EQV VILANTEROL
Last updated 28 July 2026
Product Info
ANORO ELLIPTA INHALATION POWDER 62.5 MCG/25 MCG
[SIN14838P]
Product information
Active Ingredient and Strength | (UMEC STRIP) UMECLIDINIUM BROMIDE (MICRONISED) 74.2 MCG/DOSE EQV UMECLIDINIUM - 62.5 MCG/DOSE |
Dosage Form | POWDER, METERED |
Manufacturer and Country | GLAXO OPERATIONS UK LTD (TRADING AS GLAXO WELLCOME OPERATIONS) - UNITED KINGDOM |
Registration Number | SIN14838P |
Licence Holder | GLAXOSMITHKLINE PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | R03AL03 |
Prescription-only Medicines with Exemptions for Supply without Prescription | NA |
Indication
Indications
ANORO ELLIPTA is indicated for maintenance bronchodilator treatment to relieve symptoms associated with chronic obstructive pulmonary disease (COPD).
Dosing
Dosage and Administration
Pharmaceutical form: Inhalation powder, pre-dispensed
ANORO ELLIPTA is for oral inhalation only.
ANORO ELLIPTA should be administered once daily at the same time each day.
Adults
The recommended and maximum dose is one inhalation of ANORO ELLIPTA 62.5/25 micrograms once daily.
Children
Use in patients less than 18 years of age is not relevant given the indication for this product.
Elderly
No dosage adjustment is required in patients over 65 years (see Pharmacokinetics – Special Patient Populations – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Renal impairment
No dosage adjustment is required in patients with renal impairment (see Pharmacokinetics — Special Patient Populations – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Hepatic impairment
No dosage adjustment is required in patients with mild or moderate hepatic impairment. ANORO ELLIPTA has not been studied in patients with severe hepatic impairment (see Pharmacokinetics — Special Patient Populations – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Contraindications
Contraindications
ANORO ELLIPTA is contraindicated in patients with severe milk-protein allergy, or who have demonstrated hypersensitivity to either umeclidinium, vilanterol or any of the excipients in this product.